Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells

Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells

Imatinib mesylate is the leading compound to treat chronic myeloid leukemia (CML) and other cancers, through its inhibition of Bcr-Abl tyrosine kinases. However, resistance to imatinib develops frequently, particularly in late-stage disease and has necessitated the development of new Bcr-Abl inhibit...

Full description

Bibliographic Details
Main Authors: Katerina Arvaniti, Anastasia Papadioti, Maria Kinigopoulou, Vassiliki Theodorou, Konstantinos Skobridis, Georgios Tsiotis
Format: Article
Language:English
Published: MDPI AG 2014-07-01
Series:Proteomes
Subjects:
kinase inhibitors
SILAC
protein kinases
imatinib
chronic myeloid leukemia
Online Access:http://www.mdpi.com/2227-7382/2/3/363

Internet

http://www.mdpi.com/2227-7382/2/3/363

Similar Items